Bone Biologics Corp. BBLG 深 沪
已收盘 07-02 16:00:00 美东时间
1.42
+0.020
+1.43%
华盛通- 最 高1.42
- 今 开1.34
- 成交量 1.96万股
- 最 低 1.34
- 昨 收 1.40
- 总市值 254.93万
- 52周最高 4.1299
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 1.05
- 委 比 -91.36%
- 总股本 179.53万
- 历史最高 10255.68
- 量 比 0.65
- 振 幅 5.71%
- 历史最低 1.05
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bone Biologics Announces Validated Shelf Life Extension Of Its rhNELL-1 Protein Product To 29 Months
The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the
05-19 20:07
Bone Biologics Q1 EPS $(0.43) Beats $(0.54) Estimate
Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 77.6 percent increase over losses of $(1.92) per share from the
05-15 05:11
Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.20/Share Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03032026_BBLG_Sorensen.pdf
03-04 02:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Trinity Biotech (NASDAQ:TRIB) stock moved upwards by 54.7% to $1.38 du...
2025-12-24 01:05
Bone Biologics Extends Shelf Life Of rhNELL‑1 To 24 Months, Meeting Forecasts
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its
2025-12-23 21:06
Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.25 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_11172025_BBLG_Sorensen.pdf
2025-11-18 01:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares increased by 30.4% to $2.7 during ...
2025-09-04 20:08
Bone Biologics CEO Issues Stockholder Letter Highlighting NB1 Clinical Progress, Product Improvements, Year-End Enrollment Goal, Expanded Shelf Life, Interim Trial Update, And 2026 Financial Outlook
One-Year OutlookThe firm expect to achieve a number of value-creating events in the coming year under our cost-efficient business model, including the following:Adding additional hospital sites in Australia and
2025-09-04 19:08
Bone Biologics Q2 EPS $(1.33) Misses $(0.58) Estimate
Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(1.33) per share which missed the analyst consensus estimate of $(0.58) by 129.31 percent. This is a 66.92 percent increase over losses of $(4.02) per share from
2025-08-15 05:50
Why Is Bone Biologics Stock Surging On Friday?
Bone Biologics filed a USPTO patent for NELL-1 and announced a $5 million offering to support trials and expand its bone regeneration patent portfolio.
2025-06-27 22:23
